$FENC
FENNEC PHARMACEUTICALS INC.

2018 Q4 Form 10-Q Financial Statement

#000114420418059235 Filed on November 13, 2018

View on sec.gov

Income Statement

Concept 2018 Q4 2018 Q3 2018 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.380M $1.050M $1.870M
YoY Change -15.34% -37.87% 62.61%
% of Gross Profit
Research & Development $1.720M $1.798M $798.0K
YoY Change 93.26% 265.45% 139.64%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $3.110M $1.798M $798.0K
YoY Change 23.41% 265.45% 139.64%
Operating Profit -$2.848M -$2.665M
YoY Change 30.28% 80.19%
Interest Expense $120.0K $100.0K $70.00K
YoY Change -47.83% -158.82% -158.33%
% of Operating Profit
Other Income/Expense, Net $10.00K $99.00K $78.00K
YoY Change -159.64% -165.55%
Pretax Income -$2.980M -$2.750M -$2.590M
YoY Change 30.13% 17.02% 61.88%
Income Tax
% Of Pretax Income
Net Earnings -$2.980M -$2.749M -$2.587M
YoY Change 30.13% 16.88% 61.89%
Net Earnings / Revenue
Basic Earnings Per Share -$0.14 -$0.14
Diluted Earnings Per Share -$150.4K -$0.14 -$0.14
COMMON SHARES
Basic Shares Outstanding 19.73M shares 18.97M shares 18.59M shares
Diluted Shares Outstanding 18.97M shares 18.59M shares

Balance Sheet

Concept 2018 Q4 2018 Q3 2018 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $22.78M $24.52M $25.64M
YoY Change -19.39% 153.04% 150.64%
Cash & Equivalents $22.78M $24.52M $25.64M
Short-Term Investments
Other Short-Term Assets $1.000K $0.00 $4.000K
YoY Change -92.31% -100.0% -86.67%
Inventory
Prepaid Expenses $168.0K $411.0K $60.00K
Receivables
Other Receivables
Total Short-Term Assets $22.95M $24.94M $25.70M
YoY Change -19.19% 152.12% 150.49%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $5.000K $4.000K
YoY Change -350.0%
TOTAL ASSETS
Total Short-Term Assets $22.95M $24.94M $25.70M
Total Long-Term Assets $0.00 $5.000K $4.000K
Total Assets $22.95M $24.94M $25.70M
YoY Change -19.19% 152.22% 150.53%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.032M $1.866M $709.0K
YoY Change 20.7% 280.82% 136.33%
Accrued Expenses $605.0K $210.0K $138.0K
YoY Change -2.73% 23.53% 53.33%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.637M $2.076M $847.0K
YoY Change -0.43% 101.55% 46.03%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.637M $2.076M $847.0K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $1.637M $2.076M $847.0K
YoY Change -0.43% 101.55% 46.03%
SHAREHOLDERS EQUITY
Retained Earnings -$131.3M -$128.3M -$125.5M
YoY Change 8.15% 7.72%
Common Stock $151.3M $149.9M $149.1M
YoY Change 3.03% 18.31%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $21.31M $22.86M $24.86M
YoY Change
Total Liabilities & Shareholders Equity $22.95M $24.94M $25.70M
YoY Change -19.19% 152.17% 150.53%

Cashflow Statement

Concept 2018 Q4 2018 Q3 2018 Q2
OPERATING ACTIVITIES
Net Income -$2.980M -$2.749M -$2.587M
YoY Change 30.13% 16.88% 61.89%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$2.930M -$1.599M -$1.570M
YoY Change 121.97% 66.91% 128.2%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.190M $483.0K $491.0K
YoY Change -94.02% 16.67% -93.6%
NET CHANGE
Cash From Operating Activities -2.930M -$1.599M -$1.570M
Cash From Investing Activities 0.000
Cash From Financing Activities 1.190M $483.0K $491.0K
Net Change In Cash -1.740M -$1.116M -$1.079M
YoY Change -109.36% 105.15% -115.46%
FREE CASH FLOW
Cash From Operating Activities -$2.930M -$1.599M -$1.570M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
411000 USD
CY2017Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
128000 USD
CY2018Q3 us-gaap Other Assets Current
OtherAssetsCurrent
0 USD
CY2017Q4 us-gaap Other Assets Current
OtherAssetsCurrent
13000 USD
CY2018Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24524000 USD
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
28260000 USD
CY2018Q3 us-gaap Assets Current
AssetsCurrent
24935000 USD
CY2017Q4 us-gaap Assets Current
AssetsCurrent
28401000 USD
CY2018Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1866000 USD
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
855000 USD
CY2018Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
210000 USD
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
622000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
40000 USD
CY2018Q3 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
72000 USD
CY2017Q3 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
71000 USD
CY2018Q3 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
0 USD
CY2017Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
167000 USD
CY2018Q3 us-gaap Liabilities Current
LiabilitiesCurrent
2076000 USD
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1644000 USD
CY2018Q3 us-gaap Liabilities
Liabilities
2076000 USD
CY2017Q4 us-gaap Liabilities
Liabilities
1644000 USD
CY2018Q3 us-gaap Common Stock Value
CommonStockValue
104770000 USD
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
103045000 USD
CY2018Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
45118000 USD
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
43837000 USD
CY2018Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-128272000 USD
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-121368000 USD
CY2018Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1243000 USD
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1243000 USD
CY2018Q3 us-gaap Stockholders Equity
StockholdersEquity
22859000 USD
CY2018Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
24935000 USD
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
28401000 USD
CY2018Q3 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
24524000 USD
CY2017Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
28260000 USD
CY2017Q4 us-gaap Cash
Cash
255000 USD
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
18648000 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
18648000 shares
CY2018Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
18968000 shares
CY2017Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15740000 shares
CY2018Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
CY2017Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
CY2018Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
18968000 shares
CY2017Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15740000 shares
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.14
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.15
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.37
fencf Stock Options Issuance Exercised
StockOptionsIssuanceExercised
19000 shares
CY2018Q3 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
26000 USD
CY2018Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
792000 shares
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
1846000 USD
us-gaap Revenues
Revenues
0 USD
us-gaap Revenues
Revenues
0 USD
CY2018Q3 us-gaap Revenues
Revenues
0 USD
CY2017Q3 us-gaap Revenues
Revenues
0 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3285000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1050000 USD
CY2018Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1798000 USD
CY2017Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
492000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4019000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3386000 USD
CY2018Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1050000 USD
CY2017Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1694000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-7304000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-4436000 USD
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2848000 USD
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2186000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0 USD
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
155000 USD
CY2018Q3 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
351000 USD
CY2017Q3 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
177000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-4000 USD
CY2018Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2000 USD
CY2017Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1000 USD
us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
233000 USD
us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
24000 USD
CY2018Q3 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
101000 USD
CY2017Q3 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
16000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
400000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-320000 USD
CY2018Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
99000 USD
CY2017Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-166000 USD
us-gaap Net Income Loss
NetIncomeLoss
-6904000 USD
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.37
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.32
CY2018Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.14
CY2017Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.15
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.37
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.32
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
1961000 USD
CY2018Q3 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
268000 USD
CY2017Q3 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
1117000 USD
CY2018Q3 us-gaap Cash
Cash
31000 USD
CY2018Q3 us-gaap Cash
Cash
914000 CAD
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
2000 USD
CY2018Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.14
CY2017Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.15
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
18648000 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
14533000 shares
CY2018Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
18968000 shares
CY2017Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
15740000 shares
us-gaap Net Income Loss
NetIncomeLoss
-4756000 USD
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-2749000 USD
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-2352000 USD
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
167000 USD
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-340000 USD
CY2017Q3 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-183000 USD
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
243000 USD
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
552000 USD
CY2018Q3 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
46000 USD
CY2017Q3 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
210000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
1603000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
1409000 USD
CY2018Q3 us-gaap Share Based Compensation
ShareBasedCompensation
222000 USD
CY2017Q3 us-gaap Share Based Compensation
ShareBasedCompensation
907000 USD
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
283000 USD
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-13000 USD
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-1000 USD
CY2018Q3 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-4000 USD
CY2017Q3 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-4000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1011000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
248000 USD
CY2018Q3 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1157000 USD
CY2017Q3 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
196000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-412000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4896000 USD
CY2018Q1 fencf Stock Issued During Period Value Stock Warrants Exercised
StockIssuedDuringPeriodValueStockWarrantsExercised
150000 USD
CY2018Q2 fencf Stock Issued During Period Shares Stock Warrants Exercised
StockIssuedDuringPeriodSharesStockWarrantsExercised
438000 shares
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-1568000 USD
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-2587000 USD
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
25663000 USD
CY2018Q2 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
18000 USD
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
24857000 USD
CY2018Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19104000 shares
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
18411000 shares
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2321000 USD
CY2018Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1599000 USD
CY2017Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-958000 USD
CY2018Q3 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
483000 USD
CY2017Q3 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
383000 USD
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
1142000 USD
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
512000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1160000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
8083000 USD
CY2018Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
483000 USD
CY2017Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
414000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-3736000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
5762000 USD
CY2018Q3 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-1116000 USD
CY2017Q3 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-544000 USD
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3926000 USD
CY2018Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
25640000 USD
CY2017Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10232000 USD
CY2017Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9688000 USD
CY2018Q3 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
0 USD
CY2017Q3 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
31000 USD
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
0 USD
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
7571000 USD
CY2018Q3 fencf Proceeds From Short Swing Profit Judgment Offset With Settlement Expense
ProceedsFromShortSwingProfitJudgmentOffsetWithSettlementExpense
0 USD
CY2017Q3 fencf Proceeds From Short Swing Profit Judgment Offset With Settlement Expense
ProceedsFromShortSwingProfitJudgmentOffsetWithSettlementExpense
0 USD
fencf Proceeds From Short Swing Profit Judgment Offset With Settlement Expense
ProceedsFromShortSwingProfitJudgmentOffsetWithSettlementExpense
18000 USD
fencf Proceeds From Short Swing Profit Judgment Offset With Settlement Expense
ProceedsFromShortSwingProfitJudgmentOffsetWithSettlementExpense
0 USD
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
26757000 USD
CY2018Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
36000 USD
CY2018Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
35000 USD
CY2018Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19104000 shares
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
18411000 shares
CY2018Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
139000 USD
CY2018Q3 fencf Stock Issued During Period Value Stock Warrants Exercised
StockIssuedDuringPeriodValueStockWarrantsExercised
344000 USD
us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Use of estimates</div></div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that impact the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the interim condensed consolidated financial statements and the reported amounts of expense during the reporting period.&#160;Actual results could differ from those estimates.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; background: none;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">In the opinion of management, these unaudited interim condensed consolidated financial statements include all adjustments, which are normal and recurring in nature, necessary for the fair presentation of the Company&#8217;s financial position at September 30, 2018 and to state fairly the results for the periods presented. The most significant estimates utilized during the quarter ended September 30, 2018 included estimates necessary to value grants of stock option to contractors, employees and various contractors, disclosed in Note 5.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14533000 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14533000 shares
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.32
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00000 pure
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00000 pure
CY2018Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P7Y
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0204 pure
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.62 pure
CY2017Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P7Y
fencf Percentage Of Common Shares Outstanding
PercentageOfCommonSharesOutstanding
0.25 pure
CY2018Q3 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
24524000 USD
CY2018Q3 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2017Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2018Q3 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
0 USD
CY2017Q3 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-183000 USD
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
167000 USD
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-340000 USD
CY2017Q4 fencf Stock Options Issuance
StockOptionsIssuance
19000 shares
CY2017Q4 fencf Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding And Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice
1.71
CY2018Q1 fencf Stock Issuance Granted
StockIssuanceGranted
0 shares
CY2018Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0
CY2018Q1 fencf Stock Options Issuance Exercised
StockOptionsIssuanceExercised
-19000 shares
CY2018Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.71
CY2018Q1 fencf Stock Options Issuance
StockOptionsIssuance
0 shares
CY2018Q1 fencf Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding And Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice
0
CY2018Q2 fencf Stock Issuance Granted
StockIssuanceGranted
0 shares
CY2018Q2 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0
CY2018Q2 fencf Stock Options Issuance Exercised
StockOptionsIssuanceExercised
0 shares
CY2018Q2 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2018Q2 fencf Stock Options Issuance
StockOptionsIssuance
0 shares
CY2018Q2 fencf Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding And Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice
0
CY2018Q3 fencf Stock Issuance Granted
StockIssuanceGranted
0 shares
CY2018Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0
CY2018Q3 fencf Stock Options Issuance Exercised
StockOptionsIssuanceExercised
0 shares
CY2018Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2018Q3 fencf Stock Options Issuance
StockOptionsIssuance
0 shares
CY2018Q3 fencf Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding And Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice
0
CY2018Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.50
dei Document Type
DocumentType
10-Q
dei Amendment Flag
AmendmentFlag
false
dei Document Period End Date
DocumentPeriodEndDate
2018-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Registrant Name
EntityRegistrantName
FENNEC PHARMACEUTICALS INC.
dei Entity Central Index Key
EntityCentralIndexKey
0001211583
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Trading Symbol
TradingSymbol
FENCF
CY2018Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
19729164 shares
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Small Business
EntitySmallBusiness
true

Files In Submission

Name View Source Status
0001144204-18-059235-index-headers.html Edgar Link pending
0001144204-18-059235-index.html Edgar Link pending
0001144204-18-059235.txt Edgar Link pending
0001144204-18-059235-xbrl.zip Edgar Link pending
fencf-20180930.xml Edgar Link completed
fencf-20180930.xsd Edgar Link pending
fencf-20180930_cal.xml Edgar Link unprocessable
fencf-20180930_def.xml Edgar Link unprocessable
fencf-20180930_lab.xml Edgar Link unprocessable
fencf-20180930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
image_001.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tv506413_10q.htm Edgar Link pending
tv506413_ex31-1.htm Edgar Link pending
tv506413_ex31-2.htm Edgar Link pending
tv506413_ex32-1.htm Edgar Link pending
tv506413_ex99-1.htm Edgar Link pending